Valid Ghana · FDA Ghana

CHLORDIAZEPOXIDE CAPSULES 10MG

CHLORDIAZEPOXIDE HYDROCHLORIDE

FDA/GD.125-10097 10MG nervous system INN generic

What it does

Chlordiazepoxide is a medication that helps relieve anxiety and aids in treating alcohol withdrawal symptoms.

Commonly used for: anxiety, alcohol withdrawal, nervousness

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/GD.125-10097
Registration date
2023-02-07
Expiry date
2027-12-31
Status
Valid
Active ingredient
CHLORDIAZEPOXIDE HYDROCHLORIDE
Dosage form
-
Strength
10MG
Pack size
-
Therapeutic class
-
ATC class (WHO)
N05BA - Benzodiazepine derivatives
Drug group
NERVOUS SYSTEM
RxNorm RxCUI
2356
Manufacturer / MAH
Letap Pharmaceuticals
Country of origin
GHANA
Manufacturer location
Graphic Rd, Accra, Ghana

Source: Food and Drugs Authority · fetched 2026-04-18 08:37:14 · updated 2026-09-18 04:00:09

Drug Interactions

48
Check interactions

Pharmacodynamic Warnings

Chlordiazepoxide appears in TABLE 11: Drugs with CNS depressant effects

Severe (9)

Benzodiazepines - increases exposure

Cobicistat moderately increases the exposure to benzodiazepines (alprazolam). Avoid.

Severe Study

Benzodiazepines - increases exposure

Ritonavir is predicted to increase the exposure to benzodiazepines (diazepam, flurazepam). Avoid.

Severe Theoretical

Benzodiazepines - increases exposure

Idelalisib moderately increases the exposure to benzodiazepines (alprazolam). Avoid.

Severe Study

Benzodiazepines - decreases exposure

Lorlatinib moderately decreases the exposure to benzodiazepines (midazolam). Avoid.

Severe Study

Benzodiazepines - decreases exposure

Lumacaftor is predicted to decrease the exposure to benzodiazepines (midazolam). Avoid.

Severe Theoretical

Benzodiazepines - increases exposure

Clarithromycin moderately increases the exposure to benzodiazepines (alprazolam). Avoid.

Severe Study

Benzodiazepines - increases exposure

Etravirine is predicted to increase the exposure to benzodiazepines (diazepam). Avoid.

Severe Theoretical

Benzodiazepines - affects effects

Efavirenzispredictedtoaltertheeffectsofbenzodiazepines (midazolam).Avoid.oTheoretical

Severe Theoretical

Benzodiazepines - increases exposure

Ribociclib moderately increases the exposure to benzodiazepines (midazolam). Avoid.

Severe Study

Moderate (16)

Benzodiazepines - increases exposure

Miconazole is predicted to increase the exposure to benzodiazepines (alprazolam). Use with caution and adjust dose.

Moderate Theoretical

Benzodiazepines - decreases exposure

Monoclonal antibodies (tocilizumab) are predicted to decrease the exposure to benzodiazepines (alprazolam, diazepam, midazolam). Monitor and adjust dose.

Moderate Theoretical

Benzodiazepines - increases exposure

Berotralstat moderately increases the exposure to benzodiazepines (midazolam). Monitor and adjust dose.

Moderate Study

Benzodiazepines - increases concentration

Cenobamate might increase the concentration of benzodiazepines (clobazam). Monitor and adjust dose. Also see TABLE 11 p. 1519.

Moderate Theoretical

Benzodiazepines - decreases exposure

Cenobamatemoderatelydecreasestheexposureto benzodiazepines(midazolam).Adjustdose.oStudy → AlsoseeTABLE11p.1519

Moderate Study

Unknown (23)

Antiepileptics - affects concentration

Chlordiazepoxide affects the concentration of antiepileptics (fosphenytoin, phenytoin).

Unknown Study

Benzodiazepines - decreases exposure

Apalutamide is predicted to decrease the exposure to benzodiazepines (diazepam). Avoid or monitor.

Unknown Study

Benzodiazepines - increases exposure

Dronedarone is predicted to increase the exposure to benzodiazepines (alprazolam).

Unknown Study

Benzodiazepines - increases concentration

Stiripentol increases the concentration of benzodiazepines (clobazam).

Unknown Study

Benzodiazepines - increases exposure

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to benzodiazepines (alprazolam).

Unknown Study

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Chlordiazepoxide is a medication that helps relieve anxiety and aids in treating alcohol withdrawal symptoms.

What it treats

  • anxiety
  • alcohol withdrawal
  • nervousness

How it works

It works by calming the brain and nerves, helping to reduce feelings of anxiety.

Who it's for

It's used for adults who need help managing anxiety or alcohol withdrawal.

Drug class

Benzodiazepines

Cautions

  • • Avoid using with other drugs that can cause drowsiness or sedation.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: chlordiazepoxide

BNF-referenced

Chlordiazepoxide is a medication belonging to the benzodiazepine class, primarily used for its anxiolytic, sedative, and muscle relaxant properties. It was one of the first benzodiazepines developed and is often used in the management of anxiety disorders, alcohol withdrawal symptoms, and as a premedication for surgical procedures. Chlordiazepoxide works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased neuronal inhibition and a calming effect.

Indications

  • Anxiety disorders
  • Alcohol withdrawal syndrome
  • Preoperative sedation
  • Muscle spasms

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing information.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Chlordiazepoxide exerts its effects by binding to the benzodiazepine site on the GABA-A receptor. This results in an increase in the frequency of chloride channel opening in response to GABA, which enhances the inhibitory effects of GABA in the central nervous system. The resultant hyperpolarization of neuronal membranes leads to the anxiolytic, sedative, muscle relaxant, and anticonvulsant effects associated with this drug.

Pharmacodynamics

Chlordiazepoxide has a rapid onset of action, with effects typically observed within 30 minutes to 1 hour after oral administration. It exhibits dose-dependent effects, where lower doses primarily provide anxiolytic effects, while higher doses can lead to sedation or muscle relaxation. Tolerance may develop with prolonged use, necessitating dose adjustments or cessation of therapy.

Pharmacokinetics

Chlordiazepoxide is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2 hours after oral administration. It is extensively metabolized in the liver, primarily through oxidation, and has active metabolites that contribute to its therapeutic effects. The elimination half-life of chlordiazepoxide ranges from 5 to 30 hours, with an average of about 24 hours. The drug and its metabolites are excreted mainly in the urine.

Contra-indications

  • Myasthenia gravis
  • Severe respiratory insufficiency
  • Severe hepatic impairment
  • Sleep apnoea syndrome
  • Known hypersensitivity to chlordiazepoxide or other benzodiazepines

Adverse effects

  • Drowsiness
  • Dizziness
  • Confusion
  • Ataxia
  • Dependence
  • Withdrawal symptoms
  • Paradoxical reactions (e.g., increased anxiety, agitation)

Interactions

  • Chlordiazepoxide with antiepileptics may affect their concentration, though the specific effects are unknown
  • Co-administration with fosphenytoin may affect concentration, details unknown
  • Phenytoin may also interact with chlordiazepoxide, affecting its concentration
  • Rifampicin may decrease the exposure of chlordiazepoxide

Precautions

  • Caution in patients with a history of substance abuse
  • Use with caution in elderly patients due to increased sensitivity
  • Monitor for signs of dependence and withdrawal
  • Caution in patients with a history of depression or suicidal ideation

Pregnancy

Chlordiazepoxide is not recommended during pregnancy due to potential risks to the fetus, including the possibility of congenital malformations and neonatal withdrawal syndrome.

Breast-feeding

Chlordiazepoxide is excreted in breast milk and may affect a nursing infant; caution is advised if used while breastfeeding.

Storage

Store in a cool, dry place, away from direct light. Keep out of reach of children.

Formulations

  • Oral tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: Chlordiazepoxidehydrochloride

BNF-referenced

Chlordiazepoxide hydrochloride is a benzodiazepine indicated primarily for the short-term management of anxiety and alcohol withdrawal symptoms. It acts by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased neuronal inhibition and a calming effect on the central nervous system. This medication is also used in the treatment of certain mental health disorders, although long-term use is generally discouraged due to the risk of dependence.

Indications

  • Short-term management of anxiety disorders
  • Treatment of alcohol withdrawal symptoms
  • Management of muscle spasms
  • Adjunctive treatment in certain mental health disorders

Dosage

Children: Refer to BNF for Children for appropriate dosing information.

Adults: For anxiety: 10 mg three times a day, increased if necessary to 60-100 mg daily in divided doses. For alcohol withdrawal: 10-50 mg four times a day, with dose adjustments based on clinical response.

Mechanism of action

Chlordiazepoxide enhances the action of GABA, the primary inhibitory neurotransmitter in the brain. By binding to the GABA-A receptor, it increases the frequency of chloride channel opening, leading to hyperpolarization of the neuron. This reduces neuronal excitability, contributing to its anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.

Pharmacodynamics

Chlordiazepoxide exhibits anxiolytic, sedative, muscle relaxant, anticonvulsant, and amnesic properties. Its effects are dose-dependent, with higher doses leading to increased sedation and risk of respiratory depression. The onset of action is typically within 1-2 hours, with a duration of effect ranging from several hours to a day, depending on the dose and individual metabolism.

Pharmacokinetics

Chlordiazepoxide is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring about 1-2 hours after oral administration. It undergoes extensive hepatic metabolism, primarily through cytochrome P450 enzymes, resulting in active metabolites. The drug has a half-life ranging from 5 to 30 hours, depending on individual factors, and is excreted primarily in the urine. The pharmacokinetics may be altered in individuals with hepatic impairment, necessitating dose adjustments.

Contra-indications

  • Chronic psychosis
  • Severe respiratory depression

Adverse effects

  • Menstruation irregularities
  • Urinary incontinence
  • Decreased alertness
  • Anxiety
  • Ataxia (more common in elderly)
  • Confusion
  • Gastrointestinal disorders
  • Hepatic disorders (common in elderly)
  • Depression
  • Dizziness
  • Drowsiness
  • Hyperprolactinaemia
  • Peripheral oedema
  • Dysarthria
  • Fatigue
  • Headache
  • Hypotension
  • Altered mood
  • Photosensitivity reaction
  • Suicidal thoughts
  • Muscle weakness
  • Nausea
  • Respiratory depression (particularly with high doses)
  • Anterograde amnesia
  • Abnormal behavior
  • Hallucinations
  • Libido disorder
  • Rash
  • Aggression (more common in children and elderly)
  • Blood disorders
  • Delusions
  • Jaundice
  • Paradoxical drug reactions
  • Restlessness
  • Urinary retention

Interactions

  • Increased effects when used with other CNS depressants
  • Alcohol may enhance sedation and drowsiness

Precautions

  • Caution in patients with muscle weakness
  • Caution in organic brain changes
  • Risk of dependence and withdrawal symptoms
  • Use with caution in hepatic impairment
  • Use with caution in renal impairment

Pregnancy

Avoid regular use during pregnancy. Use only if there is a clear indication, such as seizure control. High doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.

Breast-feeding

Benzodiazepines are present in breast milk and should be avoided if possible during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Tablets
BNF 85 (British National Formulary) p.398 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: chlordiazepoxide

PubChem CID 2712

Molecular formula: C16H14ClN3O

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.